📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
26 announcements match the current filters (relevance ≥ 5).
Godavari Biorefineries Q3 PBT Surges 152% to ₹21.4 Cr; EBITDA Margins Up 97 bps to 9.8%
Godavari Biorefineries reported a 152.2% YoY surge in PBT (before exceptional items) to ₹21.4 crore for Q3 FY26, driven by operating leverage and a 46% reduction in finance costs. Total income for the quarter grew 2.5% YoY to ₹461.9 crore, while EBITDA margins expanded by 97 basis points to reach 9.8%. The Bio-based Chemicals segment showed strong performance with a 76.7% YoY increase in EBITDA, and the 'Jivana' consumer brand crossed ₹100 crore revenue in 9M FY26. Despite a 56.6% drop in Ethanol segment EBITDA, the company is expanding its grain-based ethanol capacity, expected to be commissioned in Q1 FY27.
Key Highlights
Q3 FY26 PBT (before exceptional items) rose 152.2% YoY to ₹21.4 crore.
EBITDA grew 13.8% YoY to ₹45.1 crore with margins improving to 9.8%.
Finance costs significantly reduced by 46% YoY, improving overall cash flow.
Bio-based Chemicals EBITDA increased 76.7% YoY to ₹10.9 crore.
Jivana consumer brand crossed ₹100 crore revenue in 9M FY26.
👀 What to Watch
Investors should monitor the commissioning of the grain-based ethanol plant in Q1 FY27 and the continued growth of the high-margin specialty chemicals segment. The significant reduction in finance costs and the turnaround in 9M EBITDA suggest improving fundamental health.
Godavari Biorefineries Q3 Results: Revenue Up 6.7% YoY, Returns to Profit of ₹0.25 Cr
Godavari Biorefineries Limited reported a consolidated revenue of ₹459.85 crore for the quarter ended December 31, 2025, marking a 6.7% growth over the same period last year. The company successfully turned profitable, posting a net profit of ₹0.25 crore compared to a net loss of ₹15.92 crore in Q3 FY25. A significant reduction in finance costs, which fell 45.8% YoY to ₹10.21 crore, played a crucial role in the bottom-line recovery. The company also recognized a small exceptional expense of ₹0.79 crore related to the estimated impact of new labor codes.
Key Highlights
Revenue from operations grew to ₹459.85 crore in Q3 FY26 from ₹430.75 crore in Q3 FY25.
Achieved a net profit of ₹0.25 crore, recovering from a loss of ₹15.92 crore in the previous year's corresponding quarter.
Finance costs decreased significantly to ₹10.21 crore from ₹18.85 crore YoY, likely aided by IPO proceeds.
Sugar segment revenue contributed ₹339.57 crore, while Bio-based Chemicals and Distillery segments contributed ₹142.28 crore and ₹134.54 crore respectively.
Exceptional item of ₹78.72 lakhs recorded for the estimated impact of New Labour Codes.
👀 What to Watch
Investors should note the positive turnaround in profitability and the substantial reduction in interest expenses following the company's listing. Monitor the sustainability of margins in the Bio-based Chemicals and Distillery segments as they are key growth drivers beyond the seasonal sugar business.
Godavari Biorefineries Partners with Synthomer for Bio-Based Monomer Development
Godavari Biorefineries Limited (GBL) has announced a strategic partnership with London-listed Synthomer plc to develop bio-based alternatives to fossil-based monomers. Under this collaboration, GBL will supply bio-based butanol to enable Synthomer to commercialize bio-based butyl acrylate. This move targets the growing global demand for sustainable, lower-carbon chemical solutions and leverages GBL's integrated biorefinery capabilities. The partnership provides GBL with a significant global platform through Synthomer's 29 manufacturing sites across Europe, North America, and Asia.
Key Highlights
Strategic partnership with Synthomer to commercialize bio-based butyl acrylate using GBL's bio-based butanol.
Collaboration focuses on transitioning the chemical industry away from fossil-based materials toward green chemistry.
Synthomer is a major global player with approximately 3,900 employees and 29 manufacturing sites worldwide.
The initiative aligns with GBL's strategy to expand its specialty bio-based chemicals portfolio for international markets.
👀 What to Watch
This partnership validates GBL's technological capabilities in the green chemistry space and opens doors to high-value global supply chains. Investors should monitor for specific volume commitments or financial impact details in upcoming quarterly earnings calls.
Godavari Biorefineries Launches U.S. Subsidiary Sathgen Therapeutics for Global Drug Discovery
Godavari Biorefineries Limited (GBL) has incorporated Sathgen Therapeutics LLC, a wholly owned step-down subsidiary in Princeton, New Jersey. This strategic move aims to accelerate GBL's clinical-stage biotechnology programs and facilitate the global out-licensing of intellectual property. The subsidiary will focus on novel molecules targeting triple-negative breast cancer (TNBC), leveraging patents already secured in major markets including the US, Europe, and China. This expansion positions GBL to transition from a generic-focused manufacturer to a player in original drug discovery and high-value clinical partnerships.
Key Highlights
Incorporation of Sathgen Therapeutics LLC in Princeton, USA, as a wholly owned step-down subsidiary.
Secured patents in the US, Europe, and China for novel compounds targeting cancer stem cells and TNBC.
Appointment of Dr. Padmaja Ganpathy as CEO and Dr. Sendurai Mani as CSO for the U.S. entity.
Formation of a Scientific Advisory Board featuring global oncology experts Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli.
Strategic focus on global out-licensing of IP to accelerate drug-development programmes.
👀 What to Watch
Investors should monitor the company's progress in clinical trials and potential out-licensing deals, which could provide high-margin revenue streams. This move adds a high-growth biotech dimension to GBL's core biorefining and chemical business.
Godavari Biorefineries Q2 Revenue Up 34% YoY; Net Loss Narrows to ₹41.59 Crore
Godavari Biorefineries reported a strong 34% YoY growth in Q2 revenue, reaching ₹430.75 crore. While the company remains in a loss-making position, the consolidated net loss for the quarter narrowed significantly to ₹41.59 crore from ₹75 crore in the same period last year. A key operational highlight is the massive 71% reduction in inventory levels since March 2025, which helped generate a positive operating cash flow of ₹53.63 crore for the first half of the fiscal year. However, the bottom line was impacted by an exceptional expense of ₹26.66 crore during the quarter.
Key Highlights
Q2 revenue from operations increased 34.2% YoY to ₹43,075.08 Lakhs.
Consolidated net loss for Q2 narrowed to ₹4,159.24 Lakhs compared to ₹7,499.86 Lakhs YoY.
Inventory levels saw a sharp decline to ₹21,085.65 Lakhs from ₹73,871.33 Lakhs in March 2025.
Net cash inflow from operating activities for H1 FY26 improved to ₹5,363.38 Lakhs.
An exceptional expense of ₹2,665.59 Lakhs was recorded in the current quarter.
👀 What to Watch
While the narrowing losses and improved cash flow from operations are encouraging, investors should remain cautious until the company achieves consistent profitability. Monitor the impact of the exceptional items and the sustainability of revenue growth in the upcoming quarters.
Godavari Biorefineries Granted US Patent for Anti-Cancer Compounds
Godavari Biorefineries Limited has received a United States patent for "COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH" in the anti-cancer research segment. The patent covers novel chemical compounds that inhibit unregulated cell growth, targeting cancer stem cells. These compounds have shown potential for treating cancers like breast and prostate cancer. This development strengthens the company's intellectual property portfolio in a promising area of cancer research.
Key Highlights
US Patent granted for "COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH"
Patent application number is 17/415,676
PCT Filed on Dec. 16, 2019
Priority Data: Dec. 17, 2018 (IN) 201821047582
👀 What to Watch
This patent grant is a positive development. Investors should monitor further progress of these compounds in preclinical and clinical trials.
